🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Recruitingn/aAges 18 Years - anyAllargenx
NCT07264426 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged ≥18 years at time of providing informed consent * Diagnosed with CIDP * Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country * Efgartigimod treatment-naïve at time of screening Exclusion Criteria: * Polyradiculoneuropathy due to any other cause(s) * Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod
💊

What it tests

  • Efgartigimod PH20 SC
📍

Where

23 sites
PPD Virtual
Wilmington, United States
Jüdisches Krankenhaus Berlin
Berlin, Germany
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH
Bochum, Germany
UK-RUB - Katholisches Klinikum Bochum - St. Josef Hospital
Bochum, Germany
Universitätsklinikum Köln
Cologne, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
UKGM - Universitätsklinikum Gießen und Marburg GmbH
Giessen, Germany

…and 15 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy